Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad) Buy TBPH Stock  Free TBPH Stock Alerts

Theravance Biopharma (TBPH) Financials

Theravance Biopharma logo
$10.67 +0.10 (+0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$10.68 +0.01 (+0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Theravance Biopharma

Annual Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 872 -55 -56
Consolidated Net Income / (Loss)		 872 -55 -56
Net Income / (Loss) Continuing Operations		 -93 -55 -56
Total Pre-Tax Income 		-93 -49 -45
Total Operating Income		 -92 -56 -47
Total Gross Profit		 51 57 64
Total Revenue		 51 57 64
Operating Revenue		 51 57 64
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 143 113 111
Selling, General & Admin Expense		 67 70 69
Research & Development Expense		 63 41 38
Impairment Charge		 - 0.00 4.51
Restructuring Charge		 13 2.74 0.00
Total Other Income / (Expense), net		 -0.86 6.77 2.34
Interest Expense		 9.40 2.35 2.55
Other Income / (Expense), net		 8.55 9.12 4.88
Income Tax Expense		 0.01 5.92 12
Basic Earnings per Share		 $11.85 ($1.00) ($1.15)
Weighted Average Basic Shares Outstanding		 73.59M 55.30M 48.85M
Diluted Earnings per Share		 $11.85 ($1.00) ($1.15)
Weighted Average Diluted Shares Outstanding		 73.59M 55.30M 48.85M
Weighted Average Basic & Diluted Shares Outstanding		 62.86M 48.16M 49.47M

Quarterly Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 917 -10 -22 -16 -8.95 -8.51 -12 -17 -13 -16
Consolidated Net Income / (Loss)		 917 -10 -22 -16 -8.95 -8.51 -12 -17 -13 -16
Net Income / (Loss) Continuing Operations		 -16 -14 -22 -16 -8.95 -8.51 -12 -17 -13 -16
Total Pre-Tax Income 		-16 -14 -22 -14 -7.58 -5.02 -10 -15 -10 -8.94
Total Operating Income		 -14 -17 -25 -16 -8.76 -6.24 -11 -16 -11 -9.20
Total Gross Profit		 12 15 10 14 16 18 15 14 17 19
Total Revenue		 12 15 10 14 16 18 15 14 17 19
Operating Revenue		 12 15 10 14 16 18 15 14 17 19
Total Operating Expenses		 27 32 35 30 24 24 26 30 28 28
Selling, General & Admin Expense		 16 17 19 19 16 15 17 17 17 19
Research & Development Expense		 9.87 15 15 9.43 8.31 8.31 8.97 9.95 9.27 9.45
Total Other Income / (Expense), net		 -1.82 3.17 2.43 1.94 1.18 1.22 0.81 0.48 0.79 0.26
Interest Expense		 4.58 0.55 0.55 0.57 0.61 0.62 0.63 0.64 0.63 0.64
Other Income / (Expense), net		 2.76 3.72 2.98 2.50 1.79 1.85 1.43 1.13 1.42 0.90
Income Tax Expense		 0.00 -0.51 -0.40 1.46 1.37 3.49 1.26 1.31 2.65 6.59
Basic Earnings per Share		 $12.14 $0.16 ($0.35) ($0.28) ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31)
Weighted Average Basic Shares Outstanding		 75.52M 73.59M 62.93M 56.68M 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M
Diluted Earnings per Share		 $12.14 $0.16 ($0.35) ($0.28) ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31)
Weighted Average Diluted Shares Outstanding		 75.52M 73.59M 62.93M 56.68M 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M
Weighted Average Basic & Diluted Shares Outstanding		 67.37M 62.86M 57.80M 52.81M 49.80M 48.16M 48.63M 48.92M 49.17M 49.47M

Annual Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 208 -259 -1.75
Net Cash From Operating Activities		 -187 -27 -12
Net Cash From Continuing Operating Activities		 -2.43 -27 -12
Net Income / (Loss) Continuing Operations		 -93 -55 -56
Consolidated Net Income / (Loss)		 872 -55 -56
Depreciation Expense		 3.72 2.00 1.71
Amortization Expense		 3.99 2.26 1.91
Non-Cash Adjustments To Reconcile Net Income		 42 25 29
Changes in Operating Assets and Liabilities, net		 41 -0.60 12
Net Cash From Investing Activities		 1,154 -33 12
Net Cash From Continuing Investing Activities		 59 -33 12
Purchase of Property, Plant & Equipment		 -0.57 -2.49 -0.33
Purchase of Investments		 -103 -135 -141
Sale of Property, Plant & Equipment		 1.87 1.51 0.00
Sale and/or Maturity of Investments		 158 103 156
Other Investing Activities, net		 - 0.00 -2.29
Net Cash From Financing Activities		 -759 -199 -2.50
Net Cash From Continuing Financing Activities		 -739 -199 -2.50
Repurchase of Common Equity		 -129 -197 -0.45
Issuance of Common Equity		 0.80 0.62 0.61
Other Financing Activities, net		 21 -2.50 -2.66
Cash Income Taxes Paid		 118 0.02 0.11

Quarterly Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 331 -120 -111 -82 -34 -32 14 -7.49 -23 14
Net Cash From Operating Activities		 -22 -124 -11 -12 -2.49 -0.85 -1.02 -4.42 -5.20 -0.90
Net Cash From Continuing Operating Activities		 -17 55 0.00 -24 -2.49 -0.85 0.00 -5.44 -5.20 -0.90
Net Income / (Loss) Continuing Operations		 -16 -14 -22 -16 -8.95 -8.51 -12 -17 -13 -16
Consolidated Net Income / (Loss)		 917 -10 -22 -16 -8.95 -8.51 -12 -17 -13 -16
Depreciation Expense		 1.11 0.66 0.63 0.55 0.43 0.39 0.43 0.43 0.43 0.42
Amortization Expense		 0.97 1.71 0.35 0.37 0.51 1.03 0.75 0.55 0.33 0.27
Non-Cash Adjustments To Reconcile Net Income		 9.88 3.87 11 6.11 3.60 3.81 7.19 7.20 4.73 10
Changes in Operating Assets and Liabilities, net		 -13 63 -1.14 -3.82 1.93 2.43 2.28 3.94 2.01 3.60
Net Cash From Investing Activities		 1,075 39 -43 11 -0.02 -0.68 17 -3.03 -17 16
Net Cash From Continuing Investing Activities		 -20 39 0.00 -32 -0.02 -0.68 0.00 14 -17 16
Purchase of Property, Plant & Equipment		 0.06 -0.27 -0.94 -0.85 -0.02 -0.68 -0.09 -0.04 -0.02 -0.19
Purchase of Investments		 -39 -9.89 -135 -0.00 - - -27 -31 -45 -38
Sale and/or Maturity of Investments		 17 49 92 11 - - 44 28 27 56
Net Cash From Financing Activities		 -722 -35 -56 -81 -31 -31 -1.72 -0.04 -0.37 -0.37
Net Cash From Continuing Financing Activities		 -702 -35 0.00 -137 -31 -31 0.00 -1.76 -0.37 -0.37
Issuance of Common Equity		 0.00 0.31 - - -0.00 0.17 - - 0.03 0.16
Other Financing Activities, net		 24 -0.99 -0.89 -0.58 -0.51 -0.52 -1.27 -0.46 -0.40 -0.53
Cash Income Taxes Paid		 0.00 118 0.01 0.01 - 0.01 -0.01 0.02 - 0.10

Annual Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 607 382 354
Total Current Assets		 353 134 161
Cash & Equivalents		 298 40 38
Short-Term Investments		 29 63 51
Prepaid Expenses		 9.20 14 4.28
Other Current Assets		 17 17 68
Plant, Property, & Equipment, net		 12 9.07 7.42
Total Noncurrent Assets		 242 239 186
Other Noncurrent Operating Assets		 242 239 186
Total Liabilities & Shareholders' Equity		 607 382 354
Total Liabilities		 166 169 179
Total Current Liabilities		 29 25 32
Accounts Payable		 1.55 1.52 2.24
Accrued Expenses		 10 6.39 6.26
Current Deferred & Payable Income Tax Liabilities		 - 0.00 5.85
Current Employee Benefit Liabilities		 10 6.44 7.02
Other Current Liabilities		 6.75 10 11
Total Noncurrent Liabilities		 137 144 147
Noncurrent Deferred & Payable Income Tax Liabilities		 64 65 75
Other Noncurrent Operating Liabilities		 73 79 71
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 442 213 176
Total Preferred & Common Equity		 442 213 176
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 442 213 176
Common Stock		 1,296 1,122 1,141
Retained Earnings		 -854 -909 -966
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.07 0.01

Quarterly Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 763 539 447 414 371 362 356
Total Current Assets		 512 261 192 162 124 119 116
Cash & Equivalents		 419 188 106 72 54 46 23
Short-Term Investments		 68 54 62 62 46 50 68
Prepaid Expenses		 11 7.81 8.76 11 9.66 8.93 8.27
Other Current Assets		 14 12 16 17 15 14 17
Plant, Property, & Equipment, net		 12 12 9.55 9.29 8.72 8.14 7.79
Total Noncurrent Assets		 240 265 245 243 238 235 232
Other Noncurrent Operating Assets		 240 246 245 243 238 235 232
Total Liabilities & Shareholders' Equity		 763 539 447 414 371 362 356
Total Liabilities		 283 168 166 167 166 168 170
Total Current Liabilities		 142 26 25 25 22 23 23
Accounts Payable		 5.34 2.66 1.57 2.37 1.69 1.67 1.45
Accrued Expenses		 7.97 11 8.42 6.69 4.95 4.79 3.45
Current Employee Benefit Liabilities		 7.56 5.03 5.37 6.58 4.48 5.77 7.84
Other Current Liabilities		 0.69 7.43 9.16 9.71 11 11 11
Total Noncurrent Liabilities		 141 142 142 142 145 145 147
Noncurrent Deferred & Payable Income Tax Liabilities		 63 64 65 66 67 69 72
Other Noncurrent Operating Liabilities		 78 77 77 76 78 76 75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 481 371 280 246 205 194 186
Total Preferred & Common Equity		 481 371 280 246 205 194 186
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 481 371 280 246 205 194 186
Common Stock		 1,324 1,247 1,172 1,147 1,126 1,131 1,136
Retained Earnings		 -844 -876 -892 -901 -921 -937 -950
Accumulated Other Comprehensive Income / (Loss)		 -0.12 0.05 -0.29 -0.23 -0.04 -0.02 0.05

Annual Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -7.17% 11.84% 12.12%
EBITDA Growth		 69.48% 43.65% 9.87%
EBIT Growth		 67.50% 43.75% 10.34%
NOPAT Growth		 64.33% 39.06% 16.21%
Net Income Growth		 537.32% -106.33% -2.22%
EPS Growth		 512.89% -108.44% -15.00%
Operating Cash Flow Growth		 10.04% 85.56% 57.27%
Free Cash Flow Firm Growth		 -62.34% 92.02% 73.25%
Invested Capital Growth		 143.01% -3.28% -21.14%
Revenue Q/Q Growth		 -0.58% 5.35% 1.88%
EBITDA Q/Q Growth		 36.33% 16.40% -20.43%
EBIT Q/Q Growth		 33.55% 16.57% -10.23%
NOPAT Q/Q Growth		 29.64% 16.65% -6.73%
Net Income Q/Q Growth		 2.55% 3.25% -14.20%
EPS Q/Q Growth		 4.50% -56.25% -10.58%
Operating Cash Flow Q/Q Growth		 -77.46% 82.03% -0.42%
Free Cash Flow Firm Q/Q Growth		 -4.83% 78.56% 26.76%
Invested Capital Q/Q Growth		 1,927.89% -1.39% -7.53%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 100.00%
EBITDA Margin		 -147.44% -74.29% -59.73%
Operating Margin		 -179.09% -97.58% -72.92%
EBIT Margin		 -162.45% -81.71% -65.34%
Profit (Net Income) Margin		 1,698.54% -96.11% -87.63%
Tax Burden Percent		 -939.65% 112.02% 126.46%
Interest Burden Percent		 111.27% 105.01% 106.05%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -34.88% -33.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -27.46% -8.54%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 18.03% 4.19%
Return on Equity (ROE)		 1,689.74% -16.86% -29.04%
Cash Return on Invested Capital (CROIC)		 -388.84% -31.55% -9.60%
Operating Return on Assets (OROA)		 -16.98% -9.48% -11.43%
Return on Assets (ROA)		 177.58% -11.16% -15.33%
Return on Common Equity (ROCE)		 1,689.74% -16.86% -29.04%
Return on Equity Simple (ROE_SIMPLE)		 197.40% -25.91% -32.14%
Net Operating Profit after Tax (NOPAT)		 -64 -39 -33
NOPAT Margin		 -125.37% -68.31% -51.05%
Net Nonoperating Expense Percent (NNEP)		 735.30% -7.43% -24.69%
Return On Investment Capital (ROIC_SIMPLE)		 - -18.42% -18.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 130.63% 122.07% 107.44%
R&D to Revenue		 123.46% 70.74% 58.47%
Operating Expenses to Revenue		 279.09% 197.58% 172.92%
Earnings before Interest and Taxes (EBIT)		 -83 -47 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -76 -43 -38
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.71 2.63 2.64
Price to Tangible Book Value (P/TBV)		 1.71 2.63 2.64
Price to Revenue (P/Rev)		 14.72 9.75 7.19
Price to Earnings (P/E)		 0.87 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 115.39% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.75 4.14 4.29
Enterprise Value to Revenue (EV/Rev)		 8.34 7.96 5.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -2.47 -0.66 -0.49
Leverage Ratio		 9.52 1.51 1.89
Compound Leverage Factor		 10.59 1.59 2.01
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 1.04 -1.26 -2.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 12.31 5.39 5.02
Quick Ratio		 11.40 4.14 2.75
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -445 -35 -9.49
Operating Cash Flow to CapEx		 0.00% -2,768.92% -3,474.40%
Free Cash Flow to Firm to Interest Expense		 -47.27 -15.10 -3.73
Operating Cash Flow to Interest Expense		 -19.89 -11.49 -4.53
Operating Cash Flow Less CapEx to Interest Expense		 -19.75 -11.90 -4.66
Efficiency Ratios		 - - -
Asset Turnover		 0.10 0.12 0.17
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 4.02 5.48 7.81
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 114 111 87
Invested Capital Turnover		 -0.68 0.51 0.65
Increase / (Decrease) in Invested Capital		 380 -3.75 -23
Enterprise Value (EV)		 428 457 374
Market Capitalization		 756 560 463
Book Value per Share		 $6.56 $4.28 $3.57
Tangible Book Value per Share		 $6.56 $4.28 $3.57
Total Capital		 442 213 176
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -327 -102 -88
Capital Expenditures (CapEx)		 -1.29 0.98 0.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.74 6.35 41
Debt-free Net Working Capital (DFNWC)		 325 109 129
Net Working Capital (NWC)		 325 109 129
Net Nonoperating Expense (NNE)		 -937 16 24
Net Nonoperating Obligations (NNO)		 -327 -102 -88
Total Depreciation and Amortization (D&A)		 7.71 4.26 3.62
Debt-free, Cash-free Net Working Capital to Revenue		 -5.33% 11.05% 63.11%
Debt-free Net Working Capital to Revenue		 632.47% 189.42% 200.34%
Net Working Capital to Revenue		 632.47% 189.42% 200.34%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $11.85 ($1.00) ($1.15)
Adjusted Weighted Average Basic Shares Outstanding		 73.59M 55.30M 48.85M
Adjusted Diluted Earnings per Share		 $11.85 ($1.00) ($1.15)
Adjusted Weighted Average Diluted Shares Outstanding		 73.59M 55.30M 48.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 62.86M 48.16M 49.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -55 -37 -30
Normalized NOPAT Margin		 -107.86% -64.96% -46.14%
Pre Tax Income Margin		 -180.76% -85.80% -69.30%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -8.87 -19.97 -16.52
NOPAT to Interest Expense		 -6.85 -16.69 -12.91
EBIT Less CapEx to Interest Expense		 -8.73 -20.38 -16.65
NOPAT Less CapEx to Interest Expense		 -6.71 -17.11 -13.04
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 14.77% -357.02% -0.79%

Quarterly Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -5.63% -1.99% -21.06% 24.43% 26.04% 19.91% 39.22% 3.69% 7.49% 6.77%
EBITDA Growth		 81.70% 79.20% 42.24% 32.18% 35.54% 73.77% 58.99% -7.11% -43.45% -155.41%
EBIT Growth		 78.72% 75.44% 41.66% 34.08% 39.06% 67.96% 55.44% -7.03% -35.10% -88.85%
NOPAT Growth		 73.51% 68.97% 33.07% 30.21% 38.32% 64.20% 55.01% 2.59% -23.71% -47.44%
Net Income Growth		 2,696.10% 67.65% 14.87% -91.00% -100.98% 17.87% 47.19% -5.65% -41.88% -82.46%
EPS Growth		 2,629.17% 145.71% -2.94% -154.55% -101.40% -225.00% 31.43% -21.43% -52.94% -55.00%
Operating Cash Flow Growth		 51.29% -192.35% 56.96% 15.57% 88.77% 99.31% 90.89% 64.50% -109.01% -5.62%
Free Cash Flow Firm Growth		 -297.57% -195.72% -1,302.63% -2,796.90% 63.64% 99.84% 99.54% 100.79% 108.23% 2,826.89%
Invested Capital Growth		 98.15% 143.01% 131.58% 128.29% 1,892.88% -3.28% -5.09% -13.40% -15.91% -21.14%
Revenue Q/Q Growth		 12.68% 17.65% -28.89% 31.99% 14.14% 11.93% -17.43% -1.70% 18.32% 11.18%
EBITDA Q/Q Growth		 49.97% -21.13% -84.71% 39.42% 52.45% 50.70% -234.01% -58.23% 36.31% 12.23%
EBIT Q/Q Growth		 44.61% -19.79% -59.99% 37.91% 48.79% 37.01% -122.47% -49.16% 35.36% 11.95%
NOPAT Q/Q Growth		 38.52% -22.74% -42.92% 35.28% 45.67% 28.77% -79.60% -40.14% 31.00% 15.11%
Net Income Q/Q Growth		 11,290.71% -101.13% -113.16% 29.17% 42.79% 4.92% -37.06% -41.71% 23.18% -22.28%
EPS Q/Q Growth		 11,136.36% -98.68% -318.75% 20.00% 39.29% -17.65% -20.00% -41.67% 23.53% -19.23%
Operating Cash Flow Q/Q Growth		 -50.29% -460.40% 90.95% -10.83% 80.01% 65.65% -19.67% -332.00% -17.69% 82.64%
Free Cash Flow Firm Q/Q Growth		 -1,868.22% -14.56% -21.80% -9.31% 76.16% 99.50% -257.15% 285.11% 149.62% 65.24%
Invested Capital Q/Q Growth		 98.43% 1,927.89% -3.32% 1.98% -0.52% -1.39% -5.13% -6.94% -3.40% -7.53%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -75.22% -77.45% -201.16% -92.33% -38.47% -16.94% -59.26% -95.38% -51.34% -40.53%
Operating Margin		 -114.06% -118.99% -239.15% -117.27% -55.82% -35.53% -77.27% -110.16% -64.25% -49.06%
EBIT Margin		 -91.91% -93.58% -210.55% -99.05% -44.44% -25.01% -67.39% -102.25% -55.86% -44.24%
Profit (Net Income) Margin		 7,361.91% -70.74% -212.04% -113.79% -57.03% -48.45% -80.42% -115.94% -75.28% -82.79%
Tax Burden Percent		 -5,720.72% 72.67% 98.24% 110.28% 118.03% 169.66% 112.13% 108.59% 126.32% 173.70%
Interest Burden Percent		 140.01% 104.01% 102.51% 104.17% 108.73% 114.18% 106.44% 104.42% 106.69% 107.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -40.23% -12.70% -30.89% -45.48% -27.53% -22.36%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -39.33% -10.77% -28.77% -41.28% -23.00% -12.83%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 33.60% 7.07% 18.00% 22.96% 12.00% 6.30%
Return on Equity (ROE)		 1,083.49% 1,689.74% 9,168.35% -2,494.07% -6.64% -5.63% -12.89% -22.52% -15.53% -16.06%
Cash Return on Invested Capital (CROIC)		 0.00% -388.84% -467.06% -498.56% -147.55% -31.55% -22.29% -13.54% -12.56% -9.60%
Operating Return on Assets (OROA)		 -8.14% -9.78% -22.88% -12.58% -4.12% -2.90% -9.11% -15.68% -9.17% -7.74%
Return on Assets (ROA)		 651.79% -7.40% -23.04% -14.45% -5.28% -5.62% -10.87% -17.78% -12.36% -14.48%
Return on Common Equity (ROCE)		 1,083.49% 1,689.74% 9,168.35% -2,494.07% -6.64% -5.63% -12.89% -22.52% -15.53% -16.06%
Return on Equity Simple (ROE_SIMPLE)		 176.97% 0.00% 236.40% 310.01% -23.18% 0.00% -21.85% -23.57% -26.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.94 -12 -17 -11 -6.13 -4.37 -7.84 -11 -7.59 -6.44
NOPAT Margin		 -79.84% -83.29% -167.40% -82.09% -39.07% -24.87% -54.09% -77.11% -44.97% -34.34%
Net Nonoperating Expense Percent (NNEP)		 369.13% 1.44% -3.60% -4.04% -0.91% -1.93% -2.12% -4.20% -4.54% -9.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -2.05% - - - -3.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 130.73% 114.22% 184.15% 140.21% 102.86% 88.20% 115.44% 119.64% 100.04% 98.65%
R&D to Revenue		 79.25% 104.77% 139.89% 68.55% 52.96% 47.33% 61.84% 69.82% 54.94% 50.41%
Operating Expenses to Revenue		 214.06% 218.99% 339.15% 217.27% 155.82% 135.53% 177.27% 210.16% 164.25% 149.06%
Earnings before Interest and Taxes (EBIT)		 -11 -14 -22 -14 -6.97 -4.39 -9.77 -15 -9.42 -8.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.37 -11 -21 -13 -6.04 -2.98 -8.59 -14 -8.66 -7.60
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.61 1.71 1.84 2.14 1.85 2.63 2.11 2.13 2.12 2.64
Price to Tangible Book Value (P/TBV)		 1.61 1.71 1.84 2.14 1.85 2.63 2.11 2.13 2.12 2.64
Price to Revenue (P/Rev)		 15.01 14.72 14.04 11.67 8.36 9.75 7.02 6.65 6.24 7.19
Price to Earnings (P/E)		 0.91 0.87 0.78 0.69 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 109.74% 115.39% 128.43% 145.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 3.75 3.82 3.82 2.87 4.14 3.17 3.24 3.21 4.29
Enterprise Value to Revenue (EV/Rev)		 5.58 8.34 8.69 8.40 5.90 7.96 5.40 5.10 4.79 5.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.20 -2.47 -13.53 3.10 -0.85 -0.66 -0.63 -0.56 -0.52 -0.49
Leverage Ratio		 7.43 9.52 46.78 -11.59 1.62 1.51 1.58 1.71 1.78 1.89
Compound Leverage Factor		 10.40 9.90 47.95 -12.08 1.76 1.73 1.68 1.78 1.90 2.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.70 1.42 0.64 -0.17 -0.94 -0.89 -1.50 -1.80 -1.94 -1.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.60 12.31 9.98 7.82 6.37 5.39 5.74 5.20 4.97 5.02
Quick Ratio		 3.43 11.40 9.21 6.82 5.28 4.14 4.62 4.19 3.90 2.75
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -342 -392 -478 -522 -125 -0.62 -2.22 4.11 10 17
Operating Cash Flow to CapEx		 0.00% -46,637.22% -1,541.35% 0.00% -11,838.10% -126.14% -1,123.08% -12,263.89% -34,640.00% -474.74%
Free Cash Flow to Firm to Interest Expense		 -74.79 -713.34 -868.87 -919.62 -204.45 -1.00 -3.53 6.38 16.27 26.34
Operating Cash Flow to Interest Expense		 -4.83 -225.55 -20.40 -21.89 -4.08 -1.37 -1.62 -6.86 -8.25 -1.40
Operating Cash Flow Less CapEx to Interest Expense		 -4.82 -226.04 -21.73 -21.10 -4.12 -2.46 -1.77 -6.91 -8.27 -1.70
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.09 0.10 0.11 0.13 0.09 0.12 0.14 0.15 0.16 0.17
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.70 4.02 3.83 4.64 5.15 5.48 5.91 7.01 7.40 7.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -6.25 114 111 113 112 111 105 98 94 87
Invested Capital Turnover		 -0.30 -0.68 -0.41 -0.36 1.03 0.51 0.57 0.59 0.61 0.65
Increase / (Decrease) in Invested Capital		 333 380 460 511 118 -3.75 -5.63 -15 -18 -23
Enterprise Value (EV)		 288 428 422 431 322 457 332 316 303 374
Market Capitalization		 775 756 682 598 456 560 432 412 394 463
Book Value per Share		 $6.29 $6.56 $5.89 $4.94 $4.66 $4.28 $4.25 $3.98 $3.79 $3.57
Tangible Book Value per Share		 $6.29 $6.56 $5.89 $4.94 $4.66 $4.28 $4.25 $3.98 $3.79 $3.57
Total Capital		 481 442 371 280 246 213 205 194 186 176
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -487 -327 -260 -167 -134 -102 -100 -96 -91 -88
Capital Expenditures (CapEx)		 -0.06 0.27 0.73 -0.45 0.02 0.68 0.09 0.04 0.02 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -117 -2.74 -6.11 0.01 2.32 6.35 2.66 0.28 1.68 41
Debt-free Net Working Capital (DFNWC)		 370 325 235 167 136 109 103 96 93 129
Net Working Capital (NWC)		 370 325 235 167 136 109 103 96 93 129
Net Nonoperating Expense (NNE)		 -927 -1.84 4.65 4.36 2.82 4.14 3.82 5.54 5.11 9.09
Net Nonoperating Obligations (NNO)		 -487 -327 -260 -167 -134 -102 -100 -96 -91 -88
Total Depreciation and Amortization (D&A)		 2.08 2.36 0.98 0.92 0.94 1.42 1.18 0.98 0.76 0.70
Debt-free, Cash-free Net Working Capital to Revenue		 -227.03% -5.33% -12.58% 0.01% 4.25% 11.05% 4.32% 0.46% 2.66% 63.11%
Debt-free Net Working Capital to Revenue		 715.66% 632.47% 484.18% 326.64% 250.10% 189.42% 166.85% 155.38% 147.24% 200.34%
Net Working Capital to Revenue		 715.66% 632.47% 484.18% 326.64% 250.10% 189.42% 166.85% 155.38% 147.24% 200.34%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $12.14 $0.16 ($0.35) ($0.28) ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 75.52M 73.59M 62.93M 56.68M 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M
Adjusted Diluted Earnings per Share		 $12.14 $0.16 ($0.35) ($0.28) ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 75.52M 73.59M 62.93M 56.68M 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.37M 62.86M 57.80M 52.81M 49.80M 48.16M 48.63M 48.92M 49.17M 49.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.59 -12 -16 -10 -6.13 -4.37 -7.84 -8.93 -6.49 -6.44
Normalized NOPAT Margin		 -76.98% -83.29% -156.83% -76.14% -39.07% -24.87% -54.09% -62.62% -38.49% -34.34%
Pre Tax Income Margin		 -128.69% -97.34% -215.83% -103.19% -48.32% -28.56% -71.72% -106.77% -59.59% -47.66%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -2.50 -24.93 -39.88 -23.98 -11.45 -7.05 -15.54 -22.64 -14.96 -12.90
NOPAT to Interest Expense		 -2.17 -22.18 -31.71 -19.87 -10.07 -7.01 -12.47 -17.07 -12.04 -10.02
EBIT Less CapEx to Interest Expense		 -2.49 -25.41 -41.20 -23.18 -11.49 -8.14 -15.68 -22.69 -14.98 -13.20
NOPAT Less CapEx to Interest Expense		 -2.16 -22.67 -33.03 -19.08 -10.10 -8.10 -12.62 -17.13 -12.06 -10.31
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 11.06% 14.77% 21.03% 30.48% -353.37% -357.02% -317.50% -134.93% -62.16% -0.79%

Key Financial Trends

Theravance Biopharma reported mixed results in Q4 2024, with continued top-line growth and improving cash flows overshadowed by ongoing losses. The company’s cash-rich balance sheet and strong free cash flow contrast with high R&D and SG&A spending, resulting in negative profitability metrics. Key takeaways over the last year include:

  • Revenue grew to $18.75 M in Q4 2024, up 6.8% year-over-year and 11.2% sequentially, marking a fourth consecutive quarter of top-line expansion.
  • Free cash flow to firm jumped to $16.9 M in Q4 2024 from $10.2 M in Q3, driven by non-cash adjustments and investment maturities.
  • Net cash from operating activities improved to –$0.9 M in Q4 from –$5.2 M in Q3, reflecting enhanced core cash generation.
  • Excess cash position with net debt of –$88.4 M (cash & short-term investments less liabilities), and zero long-term debt, underpins a strong liquidity runway.
  • Current ratio of ~5.0× and quick ratio of ~2.8× in Q4 2024 highlight ample near-term liquidity.
  • SG&A and R&D expenses remain high at ~99% and ~50% of revenue in Q4, consistent with the company’s heavy investment in its development pipeline.
  • Book value per share held steady at $3.57, providing a tangible equity cushion.
  • GAAP net loss widened to –$15.5 M in Q4 2024 (EPS –$0.31), driven by persistent operating expenses.
  • Operating margin was –49%, EBITDA margin –40%, and net margin –83% in Q4, underscoring structural unprofitability.
  • Return on invested capital (ROIC) remained deeply negative at –22.4% in Q4 2024, highlighting the need for continued revenue growth to offset high R&D spending.
06/24/25 11:38 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Theravance Biopharma's Financials

When does Theravance Biopharma's fiscal year end?

According to the most recent income statement we have on file, Theravance Biopharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Theravance Biopharma's net income changed over the last 2 years?

Theravance Biopharma's net income appears to be on a downward trend, with a most recent value of -$56.42 million in 2024, falling from $872.13 million in 2022. The previous period was -$55.19 million in 2023. See Theravance Biopharma's forecast for analyst expectations on what’s next for the company.

What is Theravance Biopharma's operating income?
Theravance Biopharma's total operating income in 2024 was -$46.95 million, based on the following breakdown:
  • Total Gross Profit: $64.38 million
  • Total Operating Expenses: $111.33 million
How has Theravance Biopharma's revenue changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's total revenue changed from $51.35 million in 2022 to $64.38 million in 2024, a change of 25.4%.

How much debt does Theravance Biopharma have?

Theravance Biopharma's total liabilities were at $178.62 million at the end of 2024, a 5.7% increase from 2023, and a 7.9% increase since 2022.

How much cash does Theravance Biopharma have?

In the past 2 years, Theravance Biopharma's cash and equivalents has ranged from $37.80 million in 2024 to $298.17 million in 2022, and is currently $37.80 million as of their latest financial filing in 2024.

How has Theravance Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's book value per share changed from 6.56 in 2022 to 3.57 in 2024, a change of -45.6%.


Related Companies

This page (NASDAQ:TBPH) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Special gold investment soars 2,300% ... 5,090% ... 9,850%
In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...
Weiss Ratings | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
A grave, grave error.
It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...
Porter & Company | Sponsored
Israel-Iran WAR Could Destroy Trump's Presidency
The missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...
American Alternative | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
Wall Street is using Bitcoin against you
Bitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs. At first glance, that mig...
Brownstone Research | Sponsored